ILCN Lung Cancer News
ILCN Lung Cancer News


  • What Have We Learned from the National Lung Screening Trial?

    What Have We Learned from the National Lung Screening Trial?

    Lung Cancer Risk Reduction & Prevention

    By Denise R. Aberle, MD The seminal National Lung Screening Trial (NLST) showed that lung cancer screening using low dose computed tomography (LDCT) resulted in a 20% decrease in lung cancer mortality relative to chest radiography in older, heavy smokers. Additionally, there was a relative 6.7% decrease in all-cause mortality (due largely to improved lung…


  • Small Cell Lung Cancer: The Next Challenge

    Small Cell Lung Cancer: The Next Challenge

    Regulatory Agency Perspective

    By Peter Ujhazy, MD, PhD The newfound optimism in the management of lung cancer that infused the research, clinical, and patient communities 12 years ago is still gaining momentum. Seminal findings on the predictive value of epidermal growth factor receptor mutations1,2 were followed by discoveries of other therapeutic targets (ALK, ROS1, BRAF, etc.) and by…


  • 2016 ASCO Annual Meeting

    2016 ASCO Annual Meeting

    Meeting News

    By Erik J. MacLaren, PhD This year’s annual meeting of the American Society of Clinical Oncology (ASCO) is taking place June 3–7 in Chicago. The theme of the meeting this year is Collective Wisdom: The Future of Patient-Centered Care and Research, which helps to stress the need for collaborative efforts across disciplines to advance the…


  • PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

    PD-L1 IHC Blueprint Project” Presented at the AACR Annual Meeting 2016

    Systemic, Targeted, & Immune Therapies

    By Erik J. MacLaren, PhD Immunotherapy with anti-PD-L1/PD-1 antibodies is rapidly changing the therapeutic landscape for patients with non-small cell lung cancer (NSCLC). However, selecting the most optimal patient population for those treatments remains a challenge. All pharmaceutical companies with a therapeutic antibody are pursuing a PD-L1 immunohistochemistry (IHC) assay either as a “companion” diagnostic…


  • A Practical Approach to the Evaluation of Pulmonary Nodules

    A Practical Approach to the Evaluation of Pulmonary Nodules

    Lung Cancer Risk Reduction & Prevention

    By Gerard A. Silvestri, MD, MS, FCCP A recent population-based study suggested the incidence of pulmonary nodules detected by CT is around 1.5 million per year. This finding is no surprise given the increasing use of chest CT for myriad of medical conditions and may increase even further as lung cancer screening is implemented nationally.…


  • Update on Low-Dose CT Lung Cancer Screening Implementation in the United States

    Update on Low-Dose CT Lung Cancer Screening Implementation in the United States

    Lung Cancer Risk Reduction & Prevention

    By James L. Mulshine, MD, PhD, Fred Hirsch, MD, PhD, and John K. Field, PhD, FRCPath Over the last fifteen years, the use of lowdose computed tomography (LDCT) for early lung cancer detection in high-risk individuals has moved from the seminal study arising from an NIH-funded R01 grant,1 to the publication of the validation results…


  • IASLC and APLCC Present 7th IASLC Asia Pacific Lung Cancer Conference

    IASLC and APLCC Present 7th IASLC Asia Pacific Lung Cancer Conference

    Meeting News

    By Nicola M. Parry, DVM From May 13 to 15, 2016, the 7th International Association for the Study of Lung Cancer (IASLC) Asia Pacific Lung Cancer Conference (APLCC) took place at The Empress Convention Center in Chiang Mai, Thailand. Held bi-annually, this conference is a collaborative effort between the IASLC and Asia-Pacific Oncologists with an…


  • From the Editor – Corey J. Langer

    From the Editor – Corey J. Langer

    Uncategorized

    By: Corey J. Langer, MD, FACP Professor of Medicine University of Pennsylvania Editor, IASLC Lung Cancer News Welcome to the second issue of IASLC Lung Cancer News. In concert with the American Society of Clinical Oncology Meeting and in a tribute to his lifelong contributions to thoracic research, we have included a perspective by Dr. Paul…


  • Goals, Challenges, and Progress of Cancer Core Europe

    Goals, Challenges, and Progress of Cancer Core Europe

    Lung Cancer Risk Reduction & Prevention

    By Prof. Fabien Calvo, MD, PhD Today, cancer research is facing several challenges. The genomics era has ushered in a host of new molecular therapies; however, most of these targeted agents work for a limited subset of patients. Pooling data among centers, to analyze which sequences and combination of treatments perform best for which type…


  • WCLC 2016 Together Against Lung Cancer

    WCLC 2016 Together Against Lung Cancer

    Meeting News

    Dear Colleagues, We are inviting you to take part in the IASLC 17th World Conference on Lung Cancer in Vienna, December 4-7, 2016. This Conference will be the first of the Annual Conferences, following the World Conference in Denver in 2015. We expect more than 6,000 participants from all parts of the world. The members…